Trial Search Results

Biologically Focused Therapy of Treatment-Refractory MDS Patients

This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Notable Labs Inc.

Stanford Investigator(s):


Inclusion Criteria:

   - Provide informed consent;

   - Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN
   with >= 5% blasts in the bone marrow or peripheral blood, including chronic
   myelomonocytic leukemia (CMML) 1 and 2 by WHO classification

   - Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating
   agent therapy

   - Cytogenetics reported

Exclusion Criteria:

   - Hypoplastic MDS

   - Patients without adequate marrow samples for ex vivo analysis

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jack Taw